Abstract

A large number of messengers of ion and small molecules distribute cell receptor signals into the protein effector. As a second cardinal messenger, adenosine 3’, 5’-cyclic monophosphate (cAMP) is a nucleotide active in a multitude of signal pathways. The other messengers have greater involvement in the drug receptors or receptor–ligand, decreased protein activation, and less neural pathway regulation. cAMP is a promising second messenger because it controls the activity of various proteins and enzymes and makes it a second effective messenger with greater concentration in most body tissues. Local cAMP signals have become recognized worldwide in four major diseases: cancer, cataracts, diabetes, and cardiovascular diseases. Therefore, cAMP’s current status and statics relative to its characteristics were here attempted, involving simple synthesis in different directions. A few additional cAMP-play positions are now known as the second messenger and new finders in this field and experiences with cAMP and medicaments such as salmeterol, theophylline, metoprolol, desmopressin, morphine, and ranitidine. In conjunction with the recent developments described in these studies, cAMP patents provide a clear overview of cAMP’s future business interest and require more ingenuity within the organization to transmit communications and signals through other emerging technologies, such as artificial intelligence.

Key words: Second messenger, cAMP, Drug-cAMP interaction, Cancer